Shares of a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, Emmaus Life Sciences, Inc. [OTC:EMMA] rose 1.85% to $1.6500 at the previous close.

Emmaus stock recorded 21.01K shares versus 10.69K for the 30-day Average Volumes. Emmaus stock value ranged from $0.7001 to $2.1600 in the last 52 weeks. EMMA stock rose after marketing authorization application was submitted.

The application was for what?

Emmaus is a biopharmaceutical company focused on discovering, developing, marketing, and selling treatments for rare and orphan diseases.

Emmaus recently announced that the Saudi Food and Drug Authority (SFDA) has accepted its application for Marketing Authorization (MA) for Endari in Saudi Arabia.

Typically, the SFDA’s MA approval and review process takes between 12 and 18 months. The United States Food and Drug Administration has approved Endari, an oral supplement of L-glutamine that Emmaus offers to treat sickle cell anemia in adults and pediatric patients ages five and older.

EMMA’s further plans:

The submission and approval of the marketing authorization application for Emmaus (EMMA) by the Saudi Food & Drug Authority is another milestone in its progress and commitment to serve sickle cell disease patients across the Middle East and North African region.

Throughout the Kingdom of Saudi Arabia, EMMA maintains and enhances relationships with hematologists and patients rights groups. As part of the collaboration with clinicians, Emmaus is working to provide Endari on an individual patient basis in the Kingdom and broader MENA region.